News

InnovAge Announces Participation at the 44th Annual Goldman Sachs Global Healthcare Conference

DENVER, June 05, 2023 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in…

1 year ago

NKGen Biotech Announces SNK01 Preclinical and Phase I/IIa Clinical Data Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

SANTA ANA, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (NKGen), a clinical-stage biotechnology company focused on the…

1 year ago

Enterin Announces the Start of a First-in-Human Study of ENT-03 in Obesity and Type 2 Diabetes

PHILADELPHIA, June 05, 2023 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative…

1 year ago

Timber Pharmaceuticals Announces FDA Grant of CARC Waiver for TMB-001

- Phase 3 ASCEND study of TMB-001 (topical isotretinoin) for the treatment of congenital ichthyosis is 70% enrolled - WARREN,…

1 year ago

Vor Bio to Participate in the Goldman Sachs Healthcare Conference

CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, will…

1 year ago

Carina Biotech Appoints Two New U.S. Based Biotechnology Executives to the Board of Directors

ADELAIDE, Australia, June 05, 2023 (GLOBE NEWSWIRE) -- Carina Biotech (Carina), a cell therapy immuno-oncology company, today announced the appointment…

1 year ago

IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at the 2023 ASCO Annual Meeting

100% of treated patients (n=8) to date have exceeded historical median progression-free survival, with two patients that received three doses…

1 year ago

Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference

NEEDHAM, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage…

1 year ago

Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial Under Investigation for the Treatment of Rett Syndrome

The Phase 1/2 REVEAL trial is a first-in-human, randomized, dose-escalation and dose-expansion study evaluating the safety and preliminary efficacy of…

1 year ago

Inspire Medical Systems, Inc. Announces Events at SLEEP 2023, the 37th Annual Meeting of the Associated Professional Sleep Societies

MINNEAPOLIS, June 05, 2023 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on…

1 year ago